EXTON, Pa., Aug. 30, 2022 /PRNewswire/ -- Castle Creek Biosciences announced publication of a preclinical study that found that its experimental in vivo gene therapy treatment resolved biochemical and hepatic histological markers of hereditary tyrosinemia type-1 (HT1) in a large animal model of the disease. The findings appear in the August 25 edition of Nature Communications.
The Exton, PA, biotech secured the financing from 54 investors, according to an SEC filing dated May 2. The late-stage startup had last year considered a $100 million Nasdaq debut, but in a sign of the bear market that has plagued hundreds of newly minted public biotechs, Castle Creek pulled those ambitions in the last few weeks of 2021.
Close to 6 months after it initially posted its S-1 in what was still a thriving biotech IPO market, Castle Creek Biosciences has now yanked the offering as new deals fade against the background of a hard, year-end appraisal for drug stocks.
EXTON, Pa., Oct. 21, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, today announced that the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the company a $1.825 million research grant over four years (#1R01–FD007289-01). The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Skin disease biotech Castle Creek and COVID-19 antibody maker Adagio seek $100 million IPOs. CNS-focused Eliem wants $80 million in a Nasdaq debut.
EXTON, Pa., Oct. 28, 2020 /PRNewswire/ -- Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, today announced the first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi), the company's lead gene therapy candidate formerly designated FCX-007, in recessive dystrophic epidermolysis bullosa (RDEB).
EXTON, Pa., Oct. 15, 2020 /PRNewswire/ -- Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company's investigational gene therapy, for the treatment of moderate to severe localized scleroderma.
EXTON, PA, USA I October 15, 2020 I Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company's investigational gene therapy, for the treatment of moderate to severe localized scleroderma.
Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science